Stay updated on Pembrolizumab+Bevacizumab+Cyclophosphamide in Recurrent Ovarian Ca Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab+Bevacizumab+Cyclophosphamide in Recurrent Ovarian Ca Clinical Trial page.

Latest updates to the Pembrolizumab+Bevacizumab+Cyclophosphamide in Recurrent Ovarian Ca Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedPrimary peritoneal carcinoma was added to the listed conditions and a new Resources entry for the Genetic and Rare Diseases Information Center was included; the revision notes indicate a version update from v3.4.1 to v3.4.2.SummaryDifference0.2%

- Check20 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1. This appears to be a minor backend/content management update with no changes to study content.SummaryDifference0.0%

- Check27 days agoChange DetectedUI/text updates include adding a 'Show glossary' option, updating footer/version labels to 'No FEAR Act Data' and 'Revision: v3.4.0', and a capitalization change in 'Last Update Submitted that met QC Criteria'. The changes are minor and do not affect core study information or functionality (To avoid being alerted by small changes, set an alert condition by clicking below.)SummaryDifference0.2%

- Check42 days agoChange DetectedUpdated page revision label to v3.3.4 and removed the previous v3.3.3 label. This metadata update does not alter study details, eligibility criteria, or results.SummaryDifference0.0%

- Check63 days agoChange DetectedAdded a Locations section featuring New York as a study location. Page revision updated to v3.3.3.SummaryDifference0.2%

- Check91 days agoChange DetectedThe Publications section now states that entries are automatically filled from PubMed and may not be about the study, with revision updated to v3.3.2. The older PubMed description and revision v3.2.0 were removed.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab+Bevacizumab+Cyclophosphamide in Recurrent Ovarian Ca Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Bevacizumab+Cyclophosphamide in Recurrent Ovarian Ca Clinical Trial page.